The FDA granted regular approval to venetoclax (VENCLEXTA, AbbVie Inc. and Genentech Inc.) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
Contributed Author:
The U.S. Food and Drug Administration
Topics:
More From BioPortfolio on "FDA Approves Venetoclax For Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma"